Immune Checkpoint Inhibitors in Geriatric Oncology

IF 4.7 2区医学 Q1 ONCOLOGY Current Oncology Reports Pub Date : 2024-04-08 DOI:10.1007/s11912-024-01528-3

Sarah L. Cook, Md Al Amin, Shahla Bari, Pradeep J. Poonnen, Mustafa Khasraw, Margaret O. Johnson

{"title":"Immune Checkpoint Inhibitors in Geriatric Oncology","authors":"Sarah L. Cook, Md Al Amin, Shahla Bari, Pradeep J. Poonnen, Mustafa Khasraw, Margaret O. Johnson","doi":"10.1007/s11912-024-01528-3","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>This manuscript will update prior reviews of immune checkpoint inhibitors (ICIs) in light of basic science, translational, and clinical discoveries in the field of cancer immunology and aging.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>ICIs have led to significant advancements in the treatment of cancer. Landmark trials of ICIs have cited the efficacy and toxicity experienced by older patients, but most trials are not specifically designed to address outcomes in older patients. Underlying mechanisms of aging, like cellular senescence, affect the immune system and may ultimately alter the host’s response to ICIs. Validated tools are currently used to identify older adults who may be at greater risk of developing complications from their cancer treatment.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>We review changes in the aging immune system that may alter responses to ICIs, report outcomes and toxicities in older adults from recent ICI clinical trials, and discuss clinical tools specific to older patients with cancer.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":"55 1","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-024-01528-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of Review

This manuscript will update prior reviews of immune checkpoint inhibitors (ICIs) in light of basic science, translational, and clinical discoveries in the field of cancer immunology and aging.

Recent Findings

ICIs have led to significant advancements in the treatment of cancer. Landmark trials of ICIs have cited the efficacy and toxicity experienced by older patients, but most trials are not specifically designed to address outcomes in older patients. Underlying mechanisms of aging, like cellular senescence, affect the immune system and may ultimately alter the host’s response to ICIs. Validated tools are currently used to identify older adults who may be at greater risk of developing complications from their cancer treatment.

Summary

We review changes in the aging immune system that may alter responses to ICIs, report outcomes and toxicities in older adults from recent ICI clinical trials, and discuss clinical tools specific to older patients with cancer.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

老年肿瘤学中的免疫检查点抑制剂

综述目的本手稿将根据癌症免疫学和老龄化领域的基础科学、转化和临床发现，更新以往对免疫检查点抑制剂（ICIs）的综述。具有里程碑意义的 ICIs 试验提到了老年患者的疗效和毒性，但大多数试验并不是专门针对老年患者的疗效而设计的。衰老的基本机制（如细胞衰老）会影响免疫系统，并可能最终改变宿主对 ICIs 的反应。摘要我们回顾了可能改变 ICIs 反应的衰老免疫系统的变化，报告了近期 ICI 临床试验中老年人的结果和毒性，并讨论了专门针对老年癌症患者的临床工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.